期刊文献+

Surgical management of hepatocellular carcinoma 被引量:10

Surgical management of hepatocellular carcinoma
下载PDF
导出
摘要 Hepatocellular carcinoma(HCC) is the second most common cause of death from cancer worldwide. Standard potentially curative treatments are either resection or transplantation. The aim of this paper is to provide an overview of the surgical management of HCC, as well as highlight current issues in hepatic resection and transplantation. In summary, due to the relationship between HCC and chronic liver disease, the management of HCC depends both on tumourrelated and hepatic function-related considerations. As such, HCC is currently managed largely through nonsurgical means as the criteria, in relation to the above considerations, for surgical management is still largelyrestrictive. For early stage tumours, both resection and transplantation offer fairly good survival outcomes(5 years overall survival of around 50%). Selection therefore would depend on the level of hepatic function derangement, organ availability and local expertise. Patients with intermediate stage cancers have limited options, with resection being the only potential for cure. Otherwise, locoregional therapy with transarterial chemoembolization or radiofrequency ablation are viable options. Current issues in resection and transplantation are also briefly discussed such as laparoscopic resection, ablation vs resection, anatomical vs non-anatomical resection, transplantation vs resection, living donor liver transplantation and salvage liver transplantation. Hepatocellular carcinoma (HCC) is the second mostcommon cause of death from cancer worldwide.Standard potentially curative treatments are eitherresection or transplantation. The aim of this paper isto provide an overview of the surgical managementof HCC, as well as highlight current issues in hepaticresection and transplantation. In summary, due to therelationship between HCC and chronic liver disease,the management of HCC depends both on tumourrelatedand hepatic function-related considerations. Assuch, HCC is currently managed largely through nonsurgicalmeans as the criteria, in relation to the aboveconsiderations, for surgical management is still largelyrestrictive. For early stage tumours, both resectionand transplantation offer fairly good survival outcomes(5 years overall survival of around 50%). Selectiontherefore would depend on the level of hepatic functionderangement, organ availability and local expertise.Patients with intermediate stage cancers have limitedoptions, with resection being the only potential forcure. Otherwise, locoregional therapy with transarterialchemoembolization or radiofrequency ablation are viableoptions. Current issues in resection and transplantationare also briefly discussed such as laparoscopic resection,ablation vs resection, anatomical vs non-anatomicalresection, transplantation vs resection, living donor livertransplantation and salvage liver transplantation.
出处 《World Journal of Hepatology》 CAS 2015年第2期245-252,共8页 世界肝病学杂志(英文版)(电子版)
关键词 HEPATOCELLULAR CARCINOMA LIVER surgery LIVER RESECTION LIVER TRANSPLANTATION LAPAROSCOPIC liversurgery Hepatocellular carcinoma Liver surgery Liver resection Liver transplantation Laparoscopic liver surgery
  • 相关文献

参考文献1

二级参考文献127

  • 1Jian-Yong Lei,Lu-Nan Yan,Wen-Tao Wang.Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy[J].World Journal of Gastroenterology,2013,19(27):4400-4408. 被引量:9
  • 2Jianyong Lei,Lunan Yan,Wentao Wang.Comparison of the outcomes of patients who underwent deceased-donor or living-donor liver transplantation after successful downstaging therapy[J]. European Journal of Gastroenterology & Hepatology . 2013 (11)
  • 3Truman Earl,William Chapman.Hepatocellular Carcinoma: Resection versus Transplantation[J]. Semin Liver Dis . 2013 (03)
  • 4Emmanuel Tsochatzis,Matteo Garcovich,Laura Marelli,Vassilis Papastergiou,Evangelia Fatourou,Manuel L. Rodriguez‐Peralvarez,Giacomo Germani,Neil Davies,Dominic Yu,Tu Vinh Luong,Amar P. Dhillon,Douglas Thorburn,David Patch,James O’Beirne,Tim Meyer,Andrew K. Burroughs.Transarterial embolization as neo‐adjuvant therapy pretransplantation in patients with hepatocellular carcinoma[J]. Liver Int . 2013 (6)
  • 5Kristi T. Lopez,Scott K. Kuwada,Linda L. Wong.Consequences of needle tract seeding of hepatocellular cancer after liver transplant[J]. Clin Transplant . 2013 (4)
  • 6R. Iezzi,V. Cesario,L. Siciliani,M. Campanale,A. M. Gaetano,M. Siciliano,S. Agnes,F. Giuliante,A. Grieco,M. Pompili,G. L. Rapaccini,A. Gasbarrini,L. Bonomo.Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE)[J]. La radiologia medica . 2013 (4)
  • 7Valentina Bova,Roberto Miraglia,Luigi Maruzzelli,Giovanni Battista Vizzini,Angelo Luca.Predictive Factors of Downstaging of Hepatocellular Carcinoma Beyond the Milan Criteria Treated with Intra-arterial Therapies[J]. CardioVascular and Interventional Radiology . 2013 (2)
  • 8A. W. Avolio,J. B. Halldorson,P. Burra,P. Dutkowski,S. Agnes,P. A. Clavien.Balancing Utility and Need by Means of Donor‐to‐Recipient Matching: A Challenging Problem[J]. American Journal of Transplantation . 2013 (2)
  • 9Quirino Lai,Alfonso W. Avolio,Jan Lerut,Gurusharan Singh,See Ching Chan,Pasquale B. Berloco,Giuseppe Tisone,Salvatore Agnes,Kenneth S. Chok,William Sharr,Massimo Rossi,Tommaso M. Manzia,Chung Mau Lo.Recurrence of hepatocellular cancer after liver transplantation: The role of primary resection and salvage transplantation in East and West[J]. Journal of Hepatology . 2012 (5)
  • 10Robert C. Grant,Lakhbir Sandhu,Peter R. Dixon,Paul D. Greig,David R. Grant,Ian D. McGilvray.Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta‐analysis[J]. Clin Transplant . 2012 (1)

共引文献23

同被引文献52

  • 1Choon Hua Thng,Tong San Koh,David J Collins,Dow Mu Koh.Perfusion magnetic resonance imaging of the liver[J].World Journal of Gastroenterology,2010,16(13):1598-1609. 被引量:15
  • 2Nian-Song Qian,Yong-Hui Liao,Shou-Wang Cai,Vikram Raut,Jia-Hong Dong.Comprehensive application of modern technologies in precise liver resection[J].Hepatobiliary & Pancreatic Diseases International,2013,12(3):244-250. 被引量:28
  • 3Maurizio Pompili,Giampiero Francica,Francesca Romana Ponziani,Roberto Iezzi,Alfonso Wolfango Avolio.Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation[J].World Journal of Gastroenterology,2013,19(43):7515-7530. 被引量:24
  • 4杨滔,周宁新,史宪杰,张文智,黄晓强,纪文斌,黄志强.影响原发性肝癌肝移植治疗的预后因素分析[J].消化外科,2005,4(5):311-315. 被引量:4
  • 5European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 6S P Sourbron,D L Buckley.Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability[J].Physics in Medicine and Biology.2012(2)
  • 7Jordi Bruix,Morris Sherman,Josep M Llovet,Michel Beaugrand,Riccardo Lencioni,Andrew K Burroughs,Erik Christensen,Luigi Pagliaro,Massimo Colombo,Juan Rodés.Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference[J].Journal of Hepatology.2001(3)
  • 8Toffs PS,Brix G,Buckley DL,et al.Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. Journal of Magnetic Resonance Imaging . 1999
  • 9J P B O’Connor,C J Rose,A Jackson,Y Watson,S Cheung,F Maders,B J Whitcher,C Roberts,G A Buonaccorsi,G Thompson,A R Clamp,G C Jayson,G J M Parker.DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. British Journal of Cancer . 2011
  • 10NicolasMichoux,LaurentHuwart,JorgeAbarca‐Quinones,MylèneDorvillius,LaurenceAnnet,FrankPeeters,Bernard E.Van Beers.??Transvascular and interstitial transport in rat hepatocellular carcinomas: Dynamic contrast‐enhanced MRI assessment with low‐ and high‐molecular weight agents(J)J. Magn. Reson. Imaging . 2008 (4)

引证文献10

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部